Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
54E07
- Development stage
- Preclinical
- Lead developer
- UCB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
54E07 is an anti-murine interleukin-6 (IL-6) monoclonal antibody developed by UCB. It serves as a preclinical surrogate antibody to evaluate the therapeutic effects of IL-6 cytokine blockade in mouse models of autoimmune and inflammatory diseases, such as rheumatoid arthritis and experimental autoimmune glomerulonephritis. By binding directly to murine IL-6, 54E07 prevents the cytokine from interacting with its receptor, thereby inhibiting downstream STAT3 signaling and reducing inflammatory responses.
- Other names
- 54E07 mAbanti-IL-6 mAb 54E07anti-IL6 mAb 54E07anti-IL 6 mAb 54E07anti-mouse IL-6 mAb 54E07anti-murine IL-6 mAb 54E07
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on 54E07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 54E07.